Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

Article ID	Journal	Published Year	Pages	File Type
8268490	Free Radical Biology and Medicine	2015	13 Pages	PDF

Keywords

GSK3β hK1 VDAC1 SCCHN EGFR tyrosine kinase inhibitors TKI VDAC EGFR AREs HDACi NAC PI3K Nrf2 DRI keap1 ROS SCLC Oxidative stress EMT Non-small-cell lung cancer NSCLC Small cell lung cancer combination index dose reduction index Nuclear factor-erythroid 2-related factor 2 antioxidant response elements Phosphatidylinositol 3-kinase Tyrosine kinase inhibitors histone deacetylase inhibitor N-acetyl cysteine squamous cell carcinoma of head and neck epithelial-to-mesenchymal transition Glycogen synthase kinase 3β Reactive oxygen species Epidermal growth factor receptor

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Ageing

Preview

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

Authors

Alessandra Leone, Maria Serena Roca, Chiara Ciardiello, Manuela Terranova-Barberio, Carlo Vitagliano, Gennaro Ciliberto, Rita Mancini, Elena Di Gennaro, Francesca Bruzzese, Alfredo Budillon,